Abstract
SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. This study reports the direct comparison of the SARS-CoV-2 neutralizing antibody response elicited by a protein- (NVX-CoV2373), an mRNA- (Comirnaty), and a vector-based (Vaxzevria) COVID-19 vaccine, calibrated against the WHO international SARS-CoV-2 antibody standard, and further supports the use of neutralizing antibody levels as a correlate of protection.
Highlights
SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines
The levels of SARSCoV-2 neutralizing antibodies, and antibodies binding to the S protein, have recently been identified as promising correlates of protection[12,13], i.e., measuring SARS-CoV-2 antibodies in serum samples of vaccinees enables to predict the risk of developing COVID-19
Using a pseudovirus neutralization assay, Gilbert et al found that anti-SARS-CoV-2 potencies of 8 and 140 international units per milliliter (IU/mL) correspond to 70 and 90% efficacy of the Spikevax vaccine, respectively[16]
Summary
SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. The levels of SARSCoV-2 neutralizing antibodies (nAbs), and antibodies binding to the S protein, have recently been identified as promising correlates of protection[12,13], i.e., measuring SARS-CoV-2 antibodies in serum samples of vaccinees enables to predict the risk of developing COVID-19. While the clinical evaluation of vaccine candidates regularly includes such antibody readouts, the heterogenous design of the underlying virus neutralization and binding assays limits the quantitative comparison of the primary result (e.g., the neutralization titer, or arbitrary binding units) across distinct studies.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
